Search Results - "Galland, Loick"

Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides by Bergstrom, Erik N, Abbasi, Ammal, Díaz-Gay, Marcos, Galland, Loïck, Ladoire, Sylvain, Lippman, Scott M, Alexandrov, Ludmil B

“…Cancers with homologous recombination deficiency (HRD) can benefit from platinum salts and poly(ADP-ribose) polymerase inhibitors. Standard diagnostic tests…”
Get full text

Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study by Deschênes-Simard, Xavier, Richard, Corentin, Galland, Loïck, Blais, Florence, Desilets, Antoine, Malo, Julie, Cvetkovic, Lena, Belkaid, Wiam, Elkrief, Arielle, Gagné, Andréanne, Hamel, Marc-André, Orain, Michèle, Joubert, Philippe, Ghiringhelli, François, Routy, Bertrand, Blais, Normand

“…Venous thrombotic events (VTEs) are a frequent complication of non-small cell lung cancer (NSCLC) and are associated with increased morbidity. Immune…”
Get full text

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer by Galland, Loïck, Roussot, Nicolas, Desmoulins, Isabelle, Mayeur, Didier, Kaderbhai, Courèche, Ilie, Silvia, Hennequin, Audrey, Reda, Manon, Albuisson, Juliette, Arnould, Laurent, Boidot, Romain, Truntzer, Caroline, Ghiringhelli, François, Ladoire, Sylvain

“…Breast cancer is the most frequently occurring cancer worldwide. With its increasing incidence, it is a major public health problem, with many therapeutic…”
Get full text

Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer by Galland, Loïck, Lecuelle, Julie, Favier, Laure, Fraisse, Cléa, Lagrange, Aurélie, Kaderbhai, Courèche, Truntzer, Caroline, Ghiringhelli, François

“…Monoclonal antibodies targeting PD1/PD-L1 are game changers in advanced non-small cell lung cancer (NSCLC), but biomarkers are lacking. We previously reported…”
Get full text

Real-world prevalence, treatment and survival of “high risk” early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry by Ladoire, Sylvain, Mamguem Kamga, Ariane, Galland, Loick, Desmoulins, Isabelle, Mayeur, Didier, Kaderbhai, Courèche, Ilie, Silvia Mihaelia, Hennequin, Audrey, Jankowski, Clementine, Albuisson, Juliette, Nambot, Sophie, Coutant, Charles, Arnould, Laurent, Reda, Manon, Truntzer, Caroline, Dabakuyo, Sandrine

“…The results of the OlympiA study led to the approval of a PARP inhibitor (olaparib) as adjuvant treatment for early breast cancer (eBC) at high risk of relapse…”
Get full text

Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study) by Descourt, Renaud, Perol, Maurice, Rousseau-Bussac, Gaëlle, Planchard, David, Mennecier, Bertrand, Wislez, Marie, Cortot, Alexis, Guisier, Florian, Galland, Loïck, Dô, Pascal, Schott, Roland, Dansin, Eric, Arrondeau, Jennifer, Auliac, Jean-Bernard, Chouaid, Christos

“…•Brigatinib is efficient in ALK + NSCLC pretreated with crizotinib or other ALK TKIs.•Real-world data on the efficacy of brigatinib remain rare.•Brigatinib is…”
Get full text

Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience by Baude, Jérémy, Niogret, Julie, Jacob, Pierre, Bardet, Florian, Desmoulins, Isabelle, Zanetta, Sylvie, Kaderbhai, Courèche, Galland, Loïck, Mayeur, Didier, Delattre, Benjamin, Cormier, Luc, Ladoire, Sylvain

“…Chemotherapy using carboplatin and etoposide (CE) is frequently pragmatically proposed to treat metastatic prostate cancer (mPC), both primary small-cell…”
Get full text

A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer by Roussot, Nicolas, Fumet, Jean-David, Limagne, Emeric, Thibaudin, Marion, Hervieu, Alice, Hennequin, Audrey, Zanetta, Sylvie, Dalens, Lorraine, Fourrier, Théo, Galland, Loick, Jacob, Pierre, Bertaut, Aurélie, Rederstorff, Emilie, Chevalier, Cédric, Ghirardi, Sarah, Gilbert, Elodie, Khoukaz, Azzat, Martin, Etienne, Nicolet, Constance, Quivrin, Magali, Thibouw, David, Vulquin, Noémie, Truc, Gilles, Rouffiac, Magali, Ghiringhelli, Francois, Mirjolet, Céline

“…Abstract Background Immunotherapy targeting the PD-1/PD-L1 pathway is a standard of care in a number of metastatic malignancies, but less than a fifth of…”
Get full text

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study by Descourt, Renaud, Pérol, Maurice, Rousseau-Bussac, Gaëlle, Planchard, David, Mennecier, Bertrand, Wislez, Marie, Cadranel, Jacques, Cortot, Alexis Benjamin, Guisier, Florian, Galland, Loïck, Do, Pascal, Schott, Roland, Dansin, Éric, Arrondeau, Jennifer, Auliac, Jean-Bernard, Geier, Margaux, Chouaïd, Christos

“…Brigatinib is a next-generation ALK inhibitor (ALKi) that shows efficacy in ALK inhibitor naïve and post-crizotinib ALK+ advanced NSCLCs (aNSCLCs). The…”
Get full text

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness by Barnestein, Robby, Galland, Loïck, Kalfeist, Laura, Ghiringhelli, François, Ladoire, Sylvain, Limagne, Emeric

“…With the rapid clinical development of immune checkpoint inhibitors (ICIs), the standard of care in cancer management has evolved rapidly. However,…”
Get full text

Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era by Kalfeist, Laura, Galland, Loïck, Ledys, Fanny, Ghiringhelli, François, Limagne, Emeric, Ladoire, Sylvain

“…Thanks to their anti-inflammatory, anti-oedema, and anti-allergy properties, glucocorticoids are among the most widely prescribed drugs in patients with…”
Get full text

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers by Ballot, Elise, Galland, Loïck, Mananet, Hugo, Boidot, Romain, Arnould, Laurent, Desmoulins, Isabelle, Mayeur, Didier, Kaderbhai, Courèche, Ilie, Silvia, Hennequin, Audrey, Bergeron, Anthony, Derangère, Valentin, Ghiringhelli, François, Truntzer, Caroline, Ladoire, Sylvain

“…Abstract Purpose The vast majority of research studies that have described the links between DNA damage repair or homologous recombination deficiency (HRD)…”
Get full text

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1 by Galland, Loïck, Le Page, Anne Laure, Lecuelle, Julie, Bibeau, Frederic, Oulkhouir, Youssef, Derangère, Valentin, Truntzer, Caroline, Ghiringhelli, François

“…Anti-PD1/PD-L1-directed immune checkpoint inhibitors are game changers in advanced non-small-cell lung cancer, but biomarkers are lacking. The aim of our study…”
Get full text

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing by Galland, Loïck, Ballot, Elise, Mananet, Hugo, Boidot, Romain, Lecuelle, Julie, Albuisson, Juliette, Arnould, Laurent, Desmoulins, Isabelle, Mayeur, Didier, Kaderbhai, Courèche, Ilie, Silvia, Hennequin, Audrey, Bergeron, Anthony, Derangère, Valentin, Ghiringhelli, François, Truntzer, Caroline, Ladoire, Sylvain

“…Metastatic breast cancer (MBC) is frequently managed by platinum-based chemotherapy during the disease course. The real benefit of these treatments is…”
Get full text

Simultaneous isolation of CD45 tumor-infiltrating lymphocytes, tumor cells, and associated fibroblasts from murine breast tumor model by MACS by Kalfeist, Laura, Petit, Stacy, Galland, Loïck, Ghiringhelli, François, Ladoire, Sylvain, Limagne, Emeric

“…The study of the tumor microenvironment (TME) and its interactions with cancer cells is an important issue in cancer research. Here, we present a protocol to…”
Get full text

Utility of exome sequencing in routine care for metastatic colorectal cancer by D'agay, Melchior De Giraud, Galland, Loick, Tharin, Zoe, Truntzer, Caroline, Ghiringhelli, Francois

“…Metastatic colorectal cancer (mCRC) is a heterogenous disease and its prognosis depends on clinical features, such as tumor sidedness, and whether it is…”
Get full text

Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives by Ledys, Fanny, Kalfeist, Laura, Galland, Loick, Limagne, Emeric, Ladoire, Sylvain

“…Despite a few cases of long-responder patients, immunotherapy with anti-PD-(L)1 has so far proved rather disappointing in monotherapy in metastatic breast…”
Get full text

Real-world effectiveness and safety of amivantamab for exon 20 EGFR-mutant non-small cell lung cancer (NSCLC) in French early access program: Amexon 20 GFPC by Pierret, Thomas, Guisier, Florian, Daniel, Catherine, Descourt, Renaud, Galland, Loick, Molinier, Olivier, Decroisette, Chantal, Cortot, Alexis B., Moreau, Diane, Bigay-Game, Laurence, Wislez, Marie, Cloarec, Nicolas, Curcio, Hubert, Delberghe, Nicolas, Cadranel, Jacques, Duchemann, Boris, Toffart, Anne-Claire, Moreau, Lionel, Greillier, Laurent, Auliac, Jean-Bernard

“…e20529 Background: Amivantamab is a bispecific EGFR/MET antibody approved for patients with NSCLC with EGFR exon 20 insertions. In France, early access has…”
Get full text

Abstract 1188: Identification of CXCL10-inducing chemotherapy/targeted therapy combinations for PD-1 blockade sensitization in “cold” triple negative breast cancer by Kalfeist, Laura, Petit, Stacy, Galland, Loick, Poirrier, Cyriane, Aucagne, Romain, Ghiringhelli, François, Ladoire, Sylvain, Limagne, Emeric

“…Abstract Metastatic triple-negative breast cancer (mTNBC) currently has the poorest prognosis among subtypes, with limited treatment options due to molecular…”
Get full text

Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study by Frenel, Jean-Sebastien, Zeghondy, Jean, Guerin, Catherine, Mailliez, Audrey, Volant, Elsa, Poumeaud, Francois, Patsouris, Anne, Arnedos, Monica, Bailleux, Caroline, Cabal, Julie, Galland, Loick, De nonneville, Alexandre, Guiu Lahaye, Severine, Dalenc, Florence, Pistilli, Barbara, Bachelot, Thomas, Martin, Pierre, Bocquet, Francois, Larrouquere, Louis, Loirat, Delphine

“…1014 Background: Recent guidelines have positioned T-DXd as a preferred treatment in the second line setting for HER2+ metastatic breast cancer (MBC). TTC is…”
Get full text